NJ-CELULARITY,-INC.
Celularity, Inc., a newly formed biotechnology company, today announced its acceleration of cell and tissue regenerative therapies to address unmet medical needs in cancer and chronic and degenerative disease. Celularity completed their Series A financing with contributions from several biopharma companies, including Sorrento Therapeutics, United Therapeutics Corporation and Human Longevity, Inc., and entrepreneurial investors.
Celularity has been created through the contributions of extensive intellectual property, clinical-stage assets, basic and clinical research, and development expertise including:
- Several clinical-stage immuno-oncology and regenerative medicine assets and a pipeline of pre-clinical assets
- Proprietary allogeneic (“readily accessible”) immunotherapy platform
- 200+ issued and pending patents in cell therapy; robust IP for placental stem cells
- Broad fully human antibody-CAR constructs
- IND-ready joint CD38 immuno-oncology programs
- Commercial-stage functional regeneration products Biovance® and Interfyl®* and pipeline assets
- LifeBankUSA stem cell biorepository with two decades operating expertise
Founded on the pioneering work of Robert Hariri, MD, PhD, in human placenta-derived cellular therapeutics and biomaterials, Celularity’s ability to procure placental stem cells, engineer potential therapies, and deploy potential treatments, positions it to harness the potential of the human placenta and operate along the entire value chain.
“Celularity was formed as a new biotechnology model designed to apply the necessary expertise to harness our placenta discovery platform across a range of unmet medical needs,” said Celularity Founder and Chief Executive Officer, Robert J. Hariri, MD, PhD. “With the support of our investors, we are assembling proven regenerative medicine technology and expertise with the goal of developing transformative therapies for fatal and intractable diseases.” Dr. Hariri was previously chairman, chief scientific officer and chief executive officer of Celgene Cellular Therapeutics and founder of Anthrogenesis Corporation, which Celgene acquired in 2002. Dr. Hariri is also the co-founder of Human Longevity, Inc.
The formation of Celularity leverages seminal work in the discovery of novel biologically active cell populations in the human placenta with broad therapeutic potential. Celularity will draw upon these proprietary and scalable discoveries that derive from the post-partum human placenta – an ethical and renewable source of usable biomaterials. Celularity’s development program is focused on an allogeneic platform, leveraging clinically accessible, immune-tolerant cells and biomaterials from a diverse population of informed-consent donors.
Andrew von Eschenbach, MD, among the founding members of the Celularity Board of Directors and former United States Food and Drug Administration (FDA) Commissioner and Director of the National Cancer Institute said, “The pioneering work of Celularity founder Bob Hariri has unleashed the unique properties of placental derived stem cells which have renewed hope for creating safe and effective therapies for the most challenging degenerative diseases." Dr. von Eschenbach added "Celularity with its focus on accelerating innovation in regenerative medicine can become the leading catalyst for cell therapy to address many of the world's unmet medical needs."
*Interfyl is a registered trademark of Alliqua BioMedical, Inc.
Dr. Henry Ji, President and CEO of Sorrento Therapeutics, said, “We are very excited to participate in the creation of Celularity together with Dr. Hariri and his scientific team as well as global leading biopharmaceutical companies, such as Celgene, Human Longevity Inc., and United Therapeutics. The potential for regenerative therapies in treating a wide array of chronic degenerative conditions is well known. We see important synergies for the oncology field and the potential to enhance our fight against malignant cancers. Celularity’s technologies, assets, and resources will help advance selected Sorrento cellular therapy programs and potentially transform autologous cellular therapies into affordable and accessible allogeneic cell therapies.”
About Celularity, Inc.
Celularity, headquartered in Warren, New Jersey, is a biotechnology company with proprietary, leading-edge technology and Intellectual Property to harness the power of the placenta. Their medicine asset portfolio consists of more than 200 issued or pending patents as well as pre-clinical and clinical assets including CAR constructs for allogeneic CAR-T/NK products, licenses of 100+ immunotherapy assets, and commercial stage biosourcing and functional regeneration businesses. For more information, please visit www.celularity.com . Follow Celularity on Social Media: @Celularity.
About United Therapeutics
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions.
About Sorrento Therapeutics
Sorrento is an antibody-centric, clinical stage biopharmaceutical company developing new treatments for immuno-oncology, inflammation and autoimmune diseases. Sorrento's lead product candidates include immunotherapies focused on the treatment of both solid tumors and hematological malignancies, as well as late stage pain products. For more information, please visit http://sorrentotherapeutics.com
About Human Longevity, Inc.
Human Longevity, Inc. (HLI) is the genomics-based, health intelligence company creating the world’s largest and most comprehensive database of whole genome, phenotype and clinical data. HLI is developing and applying large scale computing and machine learning to make novel discoveries to revolutionize health. In addition to the HLIQ Whole Genome and HLIQ Oncology, HLI’s business also includes the HLI Health Nucleus, a genomic powered clinical research center which uses whole genome sequence analysis, advanced clinical imaging and innovative machine learning, along with curated personal health information, to deliver the most complete picture of individual health. For more information, please visit http://www.humanlongevity.com or http://www.healthnucleus.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20170821005809/en/
Contact:
Media:
For Celularity
Olivia Goodman, 212-715-1597
olivia.goodman@finnpartners.com
or
Sorrento
Therapeutics, Inc.
Alexis Nahama, DVM, 858-203-4120
anahama@sorrentotherapeutics.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Murata Pushes Capacitor Design with World’s First 10µF/50Vdc MLCC in 0805-inch Size for Automotive Applications26.6.2025 04:00:00 CEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has announced the new GCM21BE71H106KE02 multilayer ceramic capacitor (MLCC) has entered mass production. The device is the world's first 0805-inch size (2.0 x 1.25 mm) MLCC to offer a capacitance of 10µF with a 50Vdc rating and is specifically engineered for automotive applications*. This cutting-edge product marks a significant advancement in MLCC design, delivering a smaller 0805-inch package while maintaining capacitance, voltage rating, and MLCC reliability. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250611043543/en/ [Murata Manufacturing Co., Ltd.] 10µF/50Vdc MLCC in 0805-inch Size for Automotive Applications Advancements in advanced driver-assistance systems (ADAS) and autonomous driving (AD) technologies necessitate deploying an increased number of integrated circuits (ICs) within vehicle systems. This surge in ICs simultaneously leads to a greater
Mars’ Pending Acquisition of Kellanova Clears FTC Antitrust Review26.6.2025 02:07:00 CEST | Press release
Mars, Incorporated, a family-owned, global leader in pet care, snacking and food, and Kellanova (NYSE: K), a leader in global snacking, international cereal and noodles and North America frozen foods, today announced that the U.S. Federal Trade Commission (FTC) has concluded its antitrust review of Mars’ pending acquisition of Kellanova. Poul Weihrauch,CEO & Office of the President, Mars, Incorporated, said: “We are very pleased that the FTC has completed its review of the transaction without the imposition of any condition or requiring any remedy. The transaction has now received all but one of the 28 required regulatory clearances, with only the review by the European Commission outstanding. This brings us one step closer to uniting two iconic businesses with complementary footprints and portfolios, allowing us to deliver more choice and innovation to consumers.” Steve Cahillane, Chairman, President & CEO, Kellanova, said: “This represents a significant milestone on our path to combi
VeriSilicon Expands DSP Portfolio with Silicon-Proven ZSP5000 Vision Core Seriesfor Edge Intelligence26.6.2025 02:00:00 CEST | Press release
Highly scalable architectureoptimized for computer vision and image workloads with extendable instruction set VeriSilicon (688521.SH) today released the ZSP5000 Digital Signal Processing (DSP) series IPs, which are based on its fifth-generation silicon-proven DSP architecture. This product line adopts a highly scalable and energy-efficient design, and has been deeply optimized for compute-intensive workloads such as computer vision and embedded AI. Combined with the configurable nature of the architecture, this series of IP can provide excellent solutions with both energy and computing efficiency for various edge devices. The ZSP5000 series IPs include ZSP5000, ZSP5000UL, ZSP5000L, and ZSP5000H, delivering scalable vector processing performance ranging from 32 to 256 8-bit Multiply-Accumulate (MAC) operations per cycle. For even higher performance, VeriSilicon’s multi-core ZSP5400H can combine multiple ZSP5000H cores in a multi-cluster architecture to further scale computing capability
Newpark Fluids Systems Strengthens Executive Leadership and Board to Drive Continued Growth25.6.2025 21:39:00 CEST | Press release
Newpark Fluids Systems (“Newpark” or the “Company”), a leading global independent provider of drilling and completion fluids solutions, and SCF Partners (“SCF”) are pleased to announce several key additions to the Company’s executive leadership and Board of Directors. These strategic appointments, along with significant capital investments, including the development of a leading liquid mud facility in West Texas and a new technology center of excellence in Saudi Arabia, underscore Newpark’s commitment to operational excellence, customer value, and accelerated global growth following its acquisition in 2024. Nathan Snoke has joined Newpark Fluids Systems as Senior Vice President, Western Hemisphere bringing nearly two decades of predominantly North American oilfield experience to his role, most recently holding operational and commercial leadership positions with Halliburton and Flotek. He has worked across every major U.S. shale play—from the Rockies and Permian to the Marcellus and Ha
Intelsat Partners with Whitaker Peace & Development Initiative to Expand Access to Education in East Africa25.6.2025 21:00:00 CEST | Press release
Satellite-powered connectivity will support enhanced online education in conflict-affected regions in South Sudan and Uganda Intelsat, operator of one of the world’s largest integrated satellite and terrestrial networks, announced today a groundbreaking partnership with Academy Award-winning actor and humanitarian Forest Whitaker’s nonprofit, the Whitaker Peace & Development Initiative (WPDI), to revolutionize access to education in conflict-affected regions across Africa. The collaboration will deliver for the first time high-speed internet connectivity to WPDI’s Community Learning Centers in South Sudan and Uganda, creating digital bridges to education for thousands of young people in areas where infrastructure has been insufficient or compromised. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250625237871/en/ This unprecedented effort will bring reliable internet access to communities where traditional connectivity infra
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom